Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256867 · ClinicalTrials.gov registry record · Phase 3
A Study In Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT00256867: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00256867 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 369 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00256867, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.
Primary Outcome
Median percent change from Baseline to Week 6 in LDL-c in FDC and RSG monotherapy was reported. Percent change from Baseline = 100\*(exponent \[change on log scale\]-1). Baseline assessments were recorded at Visit 3 (Week 0). For a missing Baseline value, the Baseline value were replaced by the last pre-treatment measurement, if available. The hypothesis of treatment difference was tested at a 0.05 significance level based on two-sided tests. The point estimates and corresponding 95% confidence
Interventions
- DRUG GSK523338
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2005-08-18 |
| Est. Completion | 2006-10-31 |
| Phase | Phase 3 |
What the finished NCT00256867 record still lists
NCT00256867 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which GSK523338 is the first listed.
NCT00256867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00256867 about?
NCT00256867 is a clinical study titled "A Study In Patients With Type 2 Diabetes Mellitus". This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.
What is the current status of trial NCT00256867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2005-08-18. Estimated completion is 2006-10-31.
What interventions are being tested in trial NCT00256867?
The interventions under investigation include: GSK523338 (DRUG).
Who is sponsoring clinical trial NCT00256867?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00256867's enrollment target sits among peer trials
369 995th of 2000 higher than 1,005 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI